Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Sarcoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Smoldering Multiple Myeloma 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1Kidney Neoplasms 1Glioma 1Breast Neoplasms 1

Interventions

Dexamethasone 11Lenalidomide 9Calcium Dobesilate 5carfilzomib 4daratumumab 3isatuximab 2iberdomide 2elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Leflunomide 2Denosumab 2selinexor 1pomalidomide 1piperine 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1Simvastatin 1Nivolumab 1Metformin 1Melphalan 1IPH-2101 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Cyclophosphamide 1Curcumin 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Smoldering Multiple Myeloma × AH 111585 × Clear all
NCT01571726 2019-12-16

Imaging Studies and the Development of Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡